Research
Hormonal
Weekly subcutaneous Semaglutide 2.4 mg results in a -13.7% body weight reduction.
Practitioners may consider Semaglutide as an effective weight loss therapy for women with preeclampsia.
StrongSupportsmedium confidence
Weekly subcutaneous Semaglutide 2.4 mg (-13.7% body weight)
Why this rating
Based on the mention of clinical trial data.
Source
A new era in reducing obesity and the risk of cardiovascular disease events in preeclampsia
Ayesha Malik et al. · Journal of Hypertension · 2026
cohort
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →